Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases

Journal of Clinical Oncology

Volumn 26, Issue 26, 2008, Pages 4304-4310

  Ward, Janice ^a   Guthrie, James A ^a   Sheridan, Maria B ^a   Boyes, Sheila ^a   Smith, Jonathan T ^a   Wilson, Daniel ^a   Wyatt, Judy I ^a   Treanor, Darren ^a   Robinson, Philip J ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; DIAGNOSTIC AGENT; FERRIC ION; FERRIC OXIDE;

ADULT; AGED; ARTICLE; CALCULATION; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONFIDENCE INTERVAL; DISEASE SEVERITY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER INJURY; LIVER METASTASIS; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTION; PREDICTION AND FORECASTING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINUSOIDAL OBSTRUCTIVE SYNDROME; COLORECTAL TUMOR; LIVER TUMOR; LIVER VEIN OBSTRUCTION; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; CONTRAST MEDIA; FEMALE; FERRIC COMPOUNDS; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 52049125971     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.1893     Document Type: Article

References (42)

1. Choti MA, Sitzmann JV, Tiburi MF, et at: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235; 759-766, 2002
2. Fernandez FG, Drebin JA, Linehan DC, et al: Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 240:438-447, 2004
3. Pawlik TM, Scoggins CR, Zorzi D, et al: Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715-722, 2005
4. Lévi F, Zidani R, Brienza S, et al: A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma: International Organization for Cancer Chronotherapy. Cancer 85:2532-2540, 1999
5. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
6. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000
7. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
8. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
9. Tournigand C, André T, Achille E, e al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004
10. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004
11. Seium Y, Stupp R, Ruhstaller T, et al: Cxaliplatin combined with irinotecan and 5-fluorouracil/ leucovorin (OCFL) in metastatic colorectal cancer: A phase l-ll study. Ann Oncol 16:762-766, 2005
12. Zorzi D, Laurent A, Pawlik TM, et al: Che mo-therapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94:274-286, 2007
13. Moertel CG, Fleming TR, Macdonald JS, et al: Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol 11:2386-2390, 1993
14. Sørensen P, Edal AL, Madsen EL, et al: Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil. Cancer 75:2592-2596, 1995
15. Peppercorn PD, Reznek RH, Wilson P, et al: Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 77:2008-2011, 1998
16. Kooby DA, Fong Y, Suriawinata A, et al: Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 7:1034-1044, 2003
17. Behrns KE, Tsiotos GG, DeSouza NF, et al: Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 2:292-298, 1998
18. Belghiti J, Hiramatsu K, Benoist S, et al: Seven hundred forty-seven hepatectomies in the 1990s: An update to evaluate the actual risk of liver resection. J Am Coll Surg 191:38-46, 2000
19. Parc Y, Dugue L, Farges O, et al: Preoperative systemic 5-fluorouracil does not increase the risk of liver resection. Hepatogastroenterology 47:1703-1705, 2000
20. Parikh AA, Gentner B, Wu TT, et al: Perioperative complications in patients undergoing major liver resection with our without neoadjuvant chemotherapy. J Gastrointest Surg 7:1082-1088, 2003
21. Sahajpal A, Vollmer CM Jr, Dixon E, et al: Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes. J Surg Oncol 95:22-27, 2007
22. Vauthey JN, Pawlik TM, Ribero D, et al: Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065-2072, 2006
23. Rubbia-Brandt L, Audard V, Sartoretti P, et al: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15: 460-466, 2004
24. Arotcarena R, Cales V, Berthelemy P, et al: Severe sinusoidal lesions: A serious and overlooked complication of oxaliplatin-containing chemotherapy? Gastroenterol Clin Biol 30:1313-1316, 2006
25. Tisman G, MacDonald D, Shindell N, et al: Oxaliplatin toxicity masquerading as recurrent colon cancer. J Clin Oncol 22:3202-3204, 2004
26. Hagspiel KD, Neidl KF, Eichenberger AC, et al: Detection of liver metastases: Comparison of super-paramagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. Radiology 196:471478, 1995
27. Senéterre E, Taourel P, Bouvier Y, et al: Detection of hepatic metastases: Ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology 200:785-792, 1996
28. Van Beers BE, Lacrosse M, Jamart J, et al: Detection and segmental location of malignant hepatic tumors: Comparison of ferumoxides-enhanced gradient-echo and T2-weighted spin-echo MR imaging. AJR Am J Roentgenol 168:713-717, 1997
29. Ward J, Naik KS, Guthrie JA, et al: Hepatic lesion detection: Comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis. Radiology 210:459466, 1999
30. Ba-Ssalamah A, Heinz-Peer G, Schima W, et al: Detection of focal hepatic lesions: Comparison of unenhanced and SHU 555 A-enhanced MR imaging versus biphasic helical CTAP. J Magn Reson Imaging 11:665-672, 2000
31. Reimer P, Jähnke N, Fiebich M, et al: Hepatic lesion detection and characterization: Value of non-enhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis. Radiology 217:152-158, 2000
32. Vogl TJ, Schwarz W, Blume S, et al: Preoperative evaluation of malignant liver tumors: Comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US. Eur Radiol 13:262-272, 2003
33. Ward J, Guthrie JA, Wilson D, et al: Colorectal hepatic metastases: Detection with SPIO-enhanced breath-hold MR imaging-Comparison of optimized sequences at 1.5T. Radiology 228:709-718, 2003
34. Limanond P, Raman SS, Sayre J, et al: Comparison of dynamic gadolinium-enhanced and ferumoxides-enhanced MRI of the liver on highland low-field scanners. J Magn Reson Imaging 20:640-647, 2004
35. Lencioni R, Delia Pina C, Bruix J, et al: Clinical management of hepatic malignancies: Ferucarbotran-enhanced magnetic resonance imaging versus contrast-enhanced spiral computed tomography. Dig Dis Sci 50:533-537, 2005
36. Kim TK, Lee JM, Kim CS, et al: Detection of liver metastases: Gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 15:220-228, 2005
37. Ward J, Robinson PJ, Guthrie JA, et al: Liver metastases in candidates for hepatic resection: Comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. Radiology 237:170-180, 2005
38. DeLeve LD, Shulman HM, McDonald GB: Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22:27-42, 2002
39. Bismuth H, Adam R, Lévi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224: 509-520, 1996
40. Nordlinger B, Sorbye H, Collette L, et al: Final results of the EORTC intergroup randomized phase III study 40983 (EPOC) evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol Vol 25:18s, 2007 (suppl; abstr LBA5)
41. Karoui M, Penna C, Amin-Hashem M, et al: Influence of pre-operative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243:1-7, 2006
42. Aloia T, Sebagh M, Plasse M, et al: Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in